Chronic obstructive pulmonary disease: current burden and future projections

By A. Lopez, K. Shibuya, C. Rao, Colin D Mathers, A. Hansell, L. Held, Volker J Schmid, S. Buist. European Respiratory Journal, 2006

1,440 citations recorded by the source corpus.

SERIES “THE GLOBAL BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE” Edited by K.F. Rabe and J.B. Soriano Number 2 in this Series ### Summary ⇓Information about the comparative magnitude of the burden from various diseases and injuries is a critical input into building the evidence base for health policies and programmes. Such information should be based on a critical evaluation of all available epidemiological data using standard and comparable procedures across diseases and injuries, including information on the age at death and the incidence, duration and severity of cases who do not die prematurely from the disease. A summary measure, disability-adjusted life yrs (DALYs), has been developed to simultaneously measure the amount of disease burden due to premature mortality and the amount due to the nonfatal consequences of disease. Approximately 2.7 million deaths from chronic obstructive pulmonary disease (COPD) occurred in 2000, half of them in the Western Pacific Region, with the majority of these occurring in China. About 400,000 deaths occur each year from COPD in industrialised countries. The increase in global COPD deaths between 1990 and 2000 (0.5 million) is likely to be partly real, and partly due to better methods and more extensive data availability in 2000. The regional (adult) prevalence in 2000 varied from 0.5% in parts of Africa to 3–4% in North America. ### Introduction Health systems must increasingly address a broad spectrum of health issues, ranging from epidemic outbreaks to advanced therapeutic care. They must, or should, also support disease prevention and health-promotion activities. Recognising that resources for health were unlikely to grow as quickly as demand, in 1993, the World Bank proposed a series of intervention packages for countries at different stages of development which, if implemented, would probably lead to the greatest gains in population health at affordable cost. The evidence for these recommendations was based …

Subfields: Epidemiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/7b8de42837f270b0803276e3f3b8dfd3ac8ba67b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Pulmonary and Respiratory Medicine

Citations in the corpus

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. (2008, background): “Neoplasms benign, malignant, and unspecified 18 (3) 15 (2)”
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) (2008, background): “75 million deaths annually, representing the fourth leading cause of death worldwide (1), and COPD is associated with substantial morbidity (2).”
Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (2012, background): “COPD has a high impact on patients ́ wellbeing, healthcare utilization, and mortality [2] and causes a substantial and increasing economic and social burden [3, 4].”
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. (2007, background): “A major part of the GOLD report is devoted to the clinical management of COPD and presents a management plan with four components: (1) assess and monitor disease, (2) reduce risk factors, (3) manage stable COPD, and (4) manage exacerbations.”
Mortality in COPD: role of comorbidities (2006, background): “hronic obstructive pulmonary disease (COPD) represents an increasing burden worldwide, reported to be the sixth leading cause of death in 1990 [1] and the fourth in 2000 [ 2 ].”
Analysis of the Lung Microbiome in the “Healthy” Smoker and in COPD (2011, background): “Chronic obstructive pulmonary disease (COPD) is a progressive and potentially fatal lung disease that is projected to be responsible for the fifth largest burden of disease worldwide by 2020 [1,2].”